ArticleInternational journal of molecular sciences2019
Safety Evaluation of Oral Care Probiotics
Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Long-term safety and clinical effects of probiotic supplementation in at-risk populations: a systematic review and meta-analysis.Frontiers in nutrition · 2026Pooled it
- Clinical Potential of Novel Microbial Therapeutic LP51 Based on Xerosis-Microbiome Index.Cells · 2024Trial
- Weissella as an emerging probiotic candidate for IBD: current evidence, challenges, and future perspectives".Antonie van Leeuwenhoek · 2026Review
- Preclinical Safety and Toxicological Assessment of Vitamin BMolecular nutrition & food research · 2026Article
- Screening and Evaluation In Vitro ofMicroorganisms · 2026Article
- Article
- Genomic and phenotypic analysis ofFrontiers in microbiology · 2026Article
- Transition of oral microbiome profile in HIV-infected Indonesian patients: the role of antiretroviral therapy.Journal of oral microbiology · 2026Article
- Impact of novel probiotic strains isolated from Algerian fermented butter and green tea waste on broilers' production quality.Scientific reports · 2025Article
- Safety assessment of potential probiotic lactic acid bacteria strainsFood science and biotechnology · 2025Article
- Probiotic properties ofFood science and biotechnology · 2025Article
- Safety Assessment of Levilactobacillus brevis KU15006: A Comprehensive Analysis of its Phenotypic and Genotypic Properties.Probiotics and antimicrobial proteins · 2025Article
- Characterizations of lactic acid bacteria derived from pickles and the effects of fermentation on phenolic compounds in peony flowers.Food chemistry: X · 2025Article
- Unveiling the Perspective onMicroorganisms · 2025Article
- Evaluation of Safety and Probiotic Properties ofFood science & nutrition · 2025Article
- Preventive effects ofJournal of oral microbiology · 2025Article
- In Vitro Effects ofJournal of functional biomaterials · 2024Article
- Assessment of safety and in situ antibacterial activity of Weissella cibaria strains isolated from dairy farms in Minas Gerais State, Brazil, for their food application.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- The anticancer mechanisms of exopolysaccharide from Weissella cibaria D-2 on colorectal cancer via apoptosis induction.Scientific reports · 2023Article
- Draft genome sequence and probiotic functional property analysis of Lactobacillus gasseri LM1065 for food industry applications.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Weissella cibaria CMU and CMS1 are known to exert beneficial effects on the oral cavity but have not yet been determined to be generally recognized as safe (GRAS), although they are used as commercial strains in Korea. We aimed to verify the safety of W. cibaria CMU and CMS1 strains through phenotypic and genotypic analyses. Their safety was evaluated by a minimum inhibitory concentration assay for 14 antibiotics, DNA analysis for 28 antibiotic resistance genes (ARGs) and one conjugative element, antibiotic resistance gene transferability, virulence gene analysis, hemolysis, mucin degradation, toxic metabolite production, and platelet aggregation reaction. W. cibaria CMU showed higher kanamycin resistance than the European Food Safety Authority (EFSA) cut-off, but this resistance was not transferred to the recipient strain. W. cibaria CMU and CMS1 lacked ARGs in chromosomes and plasmids, and genetic analysis confirmed that antibiotic resistance of kanamycin was an intrinsic characteristic of W. cibaria. Additionally, these strains did not harbor virulence genes associated with pathogenic bacteria and lacked toxic metabolite production, β-hemolysis, mucin degradation, bile salt deconjugation, β-glucuronidase, nitroreductase activity, gelatin liquefaction, phenylalanine degradation, and platelet aggregation. Our findings demonstrate that W. cibaria CMU and CMS1 can achieve the GRAS status in future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.